NICE Reassessing Old Cancer Fund Drugs On Value-For-Money Basis – Some Fail
Executive Summary
Britain’s NICE has begun the new HTA process for Britain’s remodeled Cancer Drugs Fund and has so far provisionally rejected three of the 35 drugs contained in the old CDF on cost-effectiveness grounds; two others got a thumbs-up after their manufacturers offered further price cuts.